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The Bcl proteins play a critical role in apoptosis, as mutations in family members interfere with normal programmed
cell death. Such events can cause cell transformation, potentially leading to cancer. Recent discoveries indicate that
some viral proteins interfere with Bcl proteins either directly or indirectly; however, these data have not been
systematically described. Some viruses encode proteins that reprogramme host cellular signalling pathways
controlling cell differentiation, proliferation, genomic integrity, cell death, and immune system recognition.
This review analyses and summarises the existing data and discusses how viral proteins interfere with normal
pro- and anti-apoptotic functions of Bcl-2 and Bcl-xL. Particularly, this article focuses on how viral proteins, such as
Herpesviruses, HTLV-1, HPV and HCV, block apoptosis and how accumulation of such interference predisposes
cancer development. Finally, we discuss possible ways to prevent and treat cancers using a combination of traditional
therapies and antiviral preparations that are effective against these viruses.
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All cancers, together, comprise the second most prevalent
cause of mortality worldwide. The development of strategies
aimed at prevention and treatment to manage this disease
critically depends on the understanding of cancerous cells
and the mechanisms through which they arise [1]. It is
becoming increasingly apparent that several viruses play
significant roles in the multistage development of malignant
cancers, where the correlation of a given virus with
an associated cancer can range from 15-100% [1].
The human body naturally produces and destroys
approximately 60 billion cells daily, and proper
homeostasis is achieved by strict control of cell turnover
[2]. Programmed cell death, or apoptosis, is an essential
mechanism for regulation of tissue homeostasis, immune
system functions, and embryo development, while
abnormal and uncontrolled cell death is a major contribut-
ing factor to several diseases and tumorigenesis [3].* Correspondence: stephanie.irving@nu.edu.kz
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unless otherwise stated.Bcl family proteins are key players in cell clearance.
Therefore, when Bcl proteins are defective, it may lead
to cancer initiation and promotion [3]. In fact, Bcl-2 was
the first apoptotic regulator to be identified. In this case, the
oncoprotein was activated via chromosome translocation
(14:18 chromosome translocation) leading to human
follicular lymphoma [3]. The role of the Bcl family in
normal cells is to regulate apoptosis by inducing or
inhibiting cell death according to environmental stimuli.
Within the Bcl family, all anti-apoptotic Bcl-2 homologues
function as oncoproteins, while pro-apoptotic and
BH3-only proteins act as tumour suppressors.
Bcl proteins form homo- and heterodimers, which
explains the neutrelising competition between these
proteins. Each protein contains up to four conserved
BH domains, which are alpha-helical segments that
mediate interactions with other proteins [4]. The
hydrophobic, C–terminal domain of these proteins
localises them to intracellular membranes, such as the outer
mitochondrial membrane, the endoplasmic reticulum,
and the nuclear envelope [4]. It is hypothesised that
anti-apoptotic proteins are initially integrated into
membranes, while pro-apoptotic members are found inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pro-apoptotic Bcl proteins undergo a conformational
change and are translocated into the mitochondrial mem-
brane where anti-apoptotic proteins already reside [5-7].
In total, the Bcl family includes more than 25
members in mammalian cells [8], which function as
a ‘life/death switch’ that integrates diverse inter- and
intracellular cues to determine whether or not the
stress apoptosis pathway should be activated. The intrinsic
apoptosis pathway is controlled by the Bcl family (Figure 1)
[9]. In response to apoptotic stimuli, the balance and
interactions of anti-apoptotic and pro-apoptotic Bcl pro-
teins influence the activation of downstream pro-apoptotic
proteins Bak (Bcl-2 homologous antagonist/killer) and
Bax (Bcl-2-associated X protein) [10]. In an activated
state, Bak and Bax change conformation and penetrate the
mitochondrial outer membrane leading to cell death
[11]. It is not fully understood how Bcl-2 regulates
this mitochondrial pathway, except that Bcl-2 blocks
the permeability of the mitochondrial outer membrane,
preventing the release of cytochrome c and other pro-
apoptotic proteins, which in turn activate proteases and
caspases (Figure 1) [11,12].
Upon viral infection, apoptosis plays a crucial role in
host defense mechanisms. One of the more successful
mechanisms used by viruses is the prevention of apoptosis
in the virally-infected host cells. It is presumed that
viruses have adapted the mechanism of inhibiting cell
death in the host cell through Bcl-2 homologues, thusFigure 1 (a) Apoptotic cell death pathways and (b) inhibition of the ainitiating their own survival in the host [13,14]. We
further analysed how viruses and their proteins interfere
with the normal pro- and anti-apoptotic functions of
Bcl-2 and Bcl-xL, propose possible treatment approaches
to affect etiology of viral disease, which target pathological
proteins and pathways, and discuss how this can be used
in anti-cancer therapy.
Epstein-Barr Virus (EBV)
Epstein-Barr virus (EBV) is a gammaherpesvirus carried
by more than 90% of the world’s population, and it is
associated with several lymphoid and epithelial malignan-
cies, including Burkitt’s lymphoma, Hodgkin’s disease, and
nasopharyngeal carcinoma [15] (Table 1). At least one
homologue of the apoptotic inhibitor Bcl-2 is encoded by
many gammaherpesviruses [16].
Previous studies have shown that EBV plays a crucial
role in establishing its own latency and in tumour
formation by interacting with host cellular factors,
where the “factors” determine the fate of the host cell and
influence the immune response to the infected host [15].
Interfering with multiple signalling pathways of the
host cell enables EBV to escape the immune defense
mechanisms of the host cell and resist apoptotic
events to establish a life-long latent infection [15].
After EBV infection, in both latent and lytic phases, host
cells express around 100 EBV proteins [15]. Some,
such as latent membrane protein 1 (LMP-1), LMP2A,
EBV encoded small RNAs-1 (EBER-1), EBER2, BARF1poptosis signalling pathway.
Table 1 Viruses and their proteins that are related to possible cancer development
Virus Proteins and viral homologues Related cancer type
Epstein-Barr virus Latent phase: latent membrane protein 1 (LMP-1),
LMP2A, EBV encoded small RNAs-1 (EBER-1), EBER2,
BARF1, Lytic phase: BZLF1 andBHRF1
Lymphoid and epithelial malignancies including Burkitt’s
lymphoma, Hodgkin’s disease, nasopharyngeal carcinoma,
brain tumours, cervical cancer, leukaemia, gastric/stomach
cancer, bladder cancer, breast cancer, colorectal cancer,
renal cell carcinoma, and non-Hodgkin’s lymphomas
Human cytomegalovirus IL-10, vMIA (viral mitochondria-located inhibitor of
apoptosis), vICA (an inhibitor of caspase activation),
c-FLIP proteins, pUL38, IE1(491a), IE2(579aa), US27,
US28, UL33, and UL78
Brain tumour, breast cancer, cervical cancer, prostate
cancer, colorectal cancer, Hodgkin’s lymphoma, lymphoma,
nasopharyngeal cancer, Kaposi’s sarcoma, skin cancer,
leukaemia, and bladder cancer.
Kaposi’s
sarcoma-associatedherpesvirus
KSBcl-2 (encoded by KSHV ORF-16) and viral FLIP
(FLICE inhibitory protein, ORFK13)
HIV-related cancers, Kaposi’s sarcoma, primary effusion
lymphomas, Castleman’s disease, multiple myeloma,
non-Hodgkin’s B-cell lymphoma, primary body cavity B-cell
lymphoma, andbladder cancer.
Human papillomavirus E6oncoprotein, E 7 oncoprotein, E5 oncoprotein Cervical cancer, squamous cell carcinomas of head, neck,
mouth, vaginal cancer, anal cancer, penile cancer, bladder
cancer, vulva cancer, non-melanoma skin cancer, breast
cancer, colorectal cancer, ovarian cancer, renal cell carcinoma,
and pancreatic carcinoma.
Human T-cell leukemia virus Tax, Rex, p12 Adult T-cell leukaemia/lymphoma and brain tumours
(astrocytoma)
Hepatitis C virus E1, E2, NS5A, KFBP38, BAX HCC, liver cancer, B- and T-cell lymphomas, pancreatic cancer,
hepatobiliary cancer, non-Hodgkin’s lymphoma, thyroid cancer
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leftward open reading frame 1) and BHRF1 (BamHI-H
right reading frame 1), mimic the structure of the
anti-apoptotic Bcl-2 proteins, and, thus, inhibit apoptosis
of the infected host cell during replication [9].
BZLF1, expressed in an early stage of infection, inhibits
MHC II-associated invariant chain (CD74) in CD4 T-cells,
resulting in downregulation of Bcl-2 and Bcl-xL expression
[15]. LMP-1 is essential for virus-induced B-cell immortal-
isation and protects B-lymphoma cell lines from apoptosis
signals in vitro via induction of cellular Bcl-2 expression
[17]. However, in epithelial cells, expression of high-levels
of LMP-1 induces apoptosis, as there is no Bcl-2 expression
to mediate the signal.
Bcl-2 has been shown to specifically block LMP-1-
mediated apoptosis in LMP-1-containing cells in which
Bcl-2 has been transfected. Moreover, co-expression of
LMP-1 and Bcl-2 allows epithelial cells to grow under
low-serum conditions [17]. Thus, Bcl-2 affects transform-
ation of LMP-1 transfected epithelial cells in two ways:
inhibition of apoptosis mediated by LMP-1 induction and
interaction with LMP-1, which contributes to cell growth.
Therefore, the process of EBV-associated epithelial cell
transformation is likely regulated by co-expression of these
two proteins. In fact, in malignant EBV-positive epithelial
tumour and nasopharyngeal carcinoma cells, LMP-1 and
Bcl-2 are frequently co-expressed [17].
The relationship between EBV and various malignancies
is emphasised with post-transplantation lymphoproliferative
disease (PTLD), as it is almost always associated with EBV
infection [18]. Bcl-2 similarly confers resistance to apoptosis
and has been implicated in the pathogenesis of a variety ofmalignancies, including lymphomas [18,19], where Bcl-2 is
expressed in the majority of lesions examined. Further,
Bcl-2 was expressed in all but one LMP-1-positive case,
and the lack of Bcl-2 expression is always associated with
the absence of LMP-1 [18].
BHRF1 is a viral protein that is a structural and functional
homologue. Bellows and colleagues determined that BHRF1
is an anti-apoptotic early lytic cycle protein, which is capable
of preventing host cell death during viral lytic replication
[20]. Both BHRF1 and Bcl-2 contain eight alpha helices and
have a similar cellular distribution, being localised mainly in
the nuclear membrane, endoplasmic reticulum, and mito-
chondria [9,15]. Both lytic and latent BHRF1 transcripts
were detected in EBV-positive B- and T-cell lymphomas.
BHRF1 acts by changing its conformation and binding to
and deactivating Bak. In cytokine-deprived cells, BHRF1
inhibits apoptosis by binding to BIM (Bcl-2 interacting
mediator of cell death) instead of Bak. In addition, BHRF1
also represses pro-apoptotic BH3-only proteins PUMA
(p53 upregulated modulator of apoptosis) and BID
(BH3 interacting domain death agonist) and induces
expression of host Bcl-2 and Bcl-xL genes [19]. The
interactions between EBV proteins and Bcl-2 are shown
in Figure 2.
Human Cytomegalovirus (HCMV)
Human cytomegalovirus (HCMV), also known as human
herpesvirus-5 (HHV-5), belongs to the Herpesviridae
family. It is prevalent, with seropositivity varying from
50–90% of the population depending on socio-economic
status. Upon infection of healthy individuals, the virus
establishes itself in the haematopoietic cell population in
Figure 2 EBV interaction with the Bcl family. BHRF1 is the viral structural and functional homologue of the human proto-oncogene Bcl-2 and
is able to blockcell death through repression of pro-apoptotic proteins BIM, PUMA, and BID and upregulation of Bcl-2 [15,21]. Activated BARF1
upregulates Bcl-2 protein levels [15]. LMP-1 upregulates Bcl-2 expression through the NF-κB/c-JNK/AP-1 pathway, while LMP2A increases expression
of Bcl-xL and Bcl-2 through the Ha-Ras, PI3K/Akt, NF-κB and Raf/MEK/ERK pathways, respectively [15]. BZLF1 represses CD74 and p65 resulting in
downregulation of Bcl-2 and Bcl-xL expression [15]. EBER1 and EBER2 allow c-MYC to stimulate oncogenesis and inhibit apoptosis [15].
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a long period of time; however, it can be life-threatening
for immunocompromised people and newborns. The virus
has an oncomodulatory role and is frequently associated
with breast, cervical, prostate, and colon cancers, brain
tumours, and Hodgkin’s lymphoma [22].
The HCMV genome is 236 kbp and consists of immedi-
ate early, and late genes, which are crucial for the regulation
of latent and lytic phases. Latency is maintained similarly to
EBV and herpes simplex virus (HSV) and, under specific
stimuli, the virus reactivates from latency to the lytic state.
The first event is the expression of immediate early (IE)
proteins from the IE locus, followed by expression of the
early and late genes in a temporal cascade [23].
One of the main features of HCMV is its ability to
inhibit apoptosis to allow additional time for further
replication, leading to viral survival. HCMV encodes
viral proteins that interfere with apoptotic pathways
and prevent cell death. Ultimately, apoptotic events
are deactivated because prosurvival proteins, such as
Bcl-2, Bcl-xL or Bfl-1/A1, are highly overexpressed in
virally infected cells (Figure 1) [24]. For example, viral gene
UL37 exon 1 encodes the viral mitochondria-localised
inhibitor of apoptosis (vMIA). This product directly
binds Bax and blocks Bax-dependent pro-apoptotic
activities using two mechanisms. The first is that
vMIA sequesters Bax, inhibiting the process of outermitochondrial membrane permeabilization. Second,
vMIA recruits Bax to the mitochondria-associated mem-
brane subcompartment of the endoplasmic reticulum,
where it is actively degraded [25].
HCMV encodes special interfering proteins, such as
vMIA, vICA (an inhibitor of caspase activation), func-
tional homologues of Bcl-2, c-FLIP proteins, pUL38, IE1
(491a), and IE2 (579aa), which specifically inhibit caspase-
dependent apoptosis, thus promoting survival of infected
cells [26]. Experimental deletion of such genes from
HCMV results in apoptosis. Fibroblasts at the G0-phase,
when infected with high levels of HCMV, undergo less cell
death and exhibit a 10-fold increase in Bcl-2 expression.
When HCMV proteins IE72, pp65, and gB are expressed,
markers of mitochondrial apoptosis (cytochrome c and
caspase 3) accumulate in cells, indicating dysfunction of
programmed cell death [27].
HCMV produces US27 and US28 proteins, which
are G protein-coupled receptors (GPCRs) that play an
important role in immunomodulation and virus per-
sistence. For instance, the US28 gene product is a
chemokine receptor that increases cell growth and
can induce apoptosis in some cells. Furthermore, expres-
sion of US27 causes upregulation of the pro-survival
factor Bcl-x, AP-1 transcription factor components
jun and fos, and the IL-6 family cytokine oncostatin M
(Figure 1) [28].
Alibek et al. Infectious Agents and Cancer 2014, 9:44 Page 5 of 13
http://www.infectagentscancer.com/content/9/1/44HCMV-infected cells interfere with NF-κB, which
promotes a mesenchymal phenotype and metastatic
spreading. The viral protein IE1 mediates the binding
of NF-κB complexes to the RELB promoter, resulting
in RelB synthesis, which then induces Bcl-2, leading
to more invasive breast cancer cells [29]. Also, in
HCMV-infected monocyte-derived macrophages, Bcl-3
is upregulated and associates with p52, which is a major
component of NF-κB in cells [30]. Thus, apoptosis of
HCMV-infected cells is affected by Bcl gene family
products, and the cells acquire malignant phenotypes.
Kaposi’s Sarcoma-Associated Herpesvirus (KSHV)
Kaposi’s sarcoma-associated herpesvirus (KSHV) belongs
to the Herpesviridae family and is also known as human
herpesvirus-8 (HHV-8). It is a rhadinovirus in the
gammaherpesviruses subfamily. KSHV is strongly associ-
ated with HIV-related cancers, Kaposi’s sarcoma, primary
effusion lymphomas, and multicentric Castleman’s disease
[31-33]. KSHV is a large, double-stranded DNA virus with
a genome containing a 140kbp unique coding region. This
region is flanked by multiple GC-rich terminal repeat
sequences and contains all of the KSHV genomic
open reading frames (ORFs) [34]. There is a clear
structural and biological similarity between KSHV and
EBV; however, KSHV latency genes show no homology to
EBV latency genes [35].
The life cycle of KSHV is biphasic with latent and lytic
phases of replication with different genes being expressed
in each phase. Therefore, like other herpesviruses, KSHV
exhibits an initial lytic infection during which the linear
viral genome is replicated, followed by lifelong latent
infection, during which episomes containing the viral
genome are produced [36]. Latency is essential for estab-
lishing persistent infection by suppressing apoptosis and for
escaping the immune response of the host. Moreover, latent
replication promotes tumour formation [37].
Many gammaherpesviruses, along with other herpesvi-
ruses, encode Bcl-2 with 20-30% homology between each
other [16]. KSHV encodes a protein with both sequence
and functional homology to human Bcl-2 [13,38].
Moreover, KSHV Bcl-2 shows structural homology to
Bcl-xL and Bax, two other members of Bcl family
[39,40]. KSHV Bcl-2 has a high degree of homology
in the BH1 and BH2 domains with limited homology to
other regions of Bcl-2 (BH3 and BH4). These conserved
BH1 and BH2 motifs are necessary for the formation of
homo- and heterodimers with other family members
[38,41]. The BH3 domain plays an anti-apoptotic role in
KSHV Bcl-2; while, in other members of the Bcl-2
family this region functions as an apoptosis trigger. This
difference is attributed to a missing non-structured loop
between the BH3 and BH4 motifs in KSHV Bcl-2, which
plays a role in the production of pro-apoptotic proteins[42]. The exact mechanism by which KSHV Bcl-2
prolongs cell survival is still unclear. Some studies assert
that KSHV Bcl-2 does not form a heterodimer with
pro-apoptotic Bcl-2 proteins. Instead, other studies reveal
heterodimerization of KSHV Bcl-2 with anti-apoptotic
Bcl-2 proteins [43,44].
KSHV viral Bcl-2 (vBcl-2) is encoded by ORF16 [34].
This lytic protein acts directly on the apoptotic pathways
via inhibition of apoptosis induced by KSHV infection and
deactivation of the pro-apoptotic protein Bax [45,46].
Introduction into yeast and human cells demonstrates that
KSHV vBcl-2 suppresses Bax toxicity, and it heterodi-
merizes with human Bcl-2 (huBcl-2) in a yeast two-hybrid
system [46,47]. Expression of KSHV vBcl-2 prolongs cell
life allowing the virus to replicate.
Another way to protect cells from apoptosis is to
express KSHV viral cyclin (v-cyclin), encoded by ORF72.
Unlike cellular Bcl-2 proteins, KSHV Bcl-2 is not a
substrate for v-cyclin –CDK6 phosphorylation and
does not contain a caspase cleavage site for production of
pro-apoptotic proteins [48,49]. Furthermore, viral FLIP
(FLICE inhibitory protein, ORFK13), as well as vBcl-2
has anti-apoptotic properties, which might contribute
to a poor prognosis in a subset of patients with Kaposi’s
sarcoma [49].
Pro- and anti-apoptotic activity of Bcl-2 family
members largely depends on mitochondria [50]. KSHV
Bcl-2 inhibits the apoptotic signalling pathway by
abrogating the function of mitochondria [13]. Repression
of anti-apoptotic activity of KSHV Bcl-2 can be achieved
by its translocation to the nucleoli via interaction with
PICT-1. Nucleolar translocation shifts KSHV Bcl-2 away
from mitochondria and, therefore, facilitates the downreg-
ulation of KSHV Bcl-2 anti-apoptotic activity [13,51].
Human Papillomavirus (HPV)
Human papillomavirus (HPV) is the most studied form of
papillomavirus. There are over 100 different types dispersed
among mammals, birds and reptiles [52]. HPV infects the
epithelial cell layer of the mouth, anus, vagina, vulva, and
cervix, as well as head, neck, and laryngeal mucosa. HPVs
are classified into supergroups, where groups A and B con-
tain the members most likely to lead to tumour formation
[53,54]. HPV 16/18, a member of supergroup A that has a
genome of about 8000 base pairs, is considered a high-risk
type of HPV that can cause cervical cancer [55]. Consisting
of small double-stranded DNA, the HPV genome encodes
six early viral proteins (E1, E2, E4, E5, E6, and E7) for DNA
replication, and two late viral proteins (L1 and L2) for pack-
aging of newly synthesised virions. The life cycle of most
HPVs is a simple process where internalisation occurs via
endocytosis of clathrin-coated vesicles [56]. After internal-
isation has occurred, viral proteins E1 and E2 are expressed
to maintain the viral genome as an episome [57].
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the life cycle of HPV 16. After internalisation into the
host cell, these proteins are involved in cell proliferation
by interaction with cell cycle regulators [58]. In particular,
E7 interacts with the pRb pocket protein blocking the E2F
transcription factor binding site, thereby promoting
expression of proteins involved in DNA replication
[59]. In addition, E7 can interfere with histone deacetylase
and cyclin-dependent kinase inhibitors like p21 and
p27, which strongly indicates the importance of E7 in
proliferation of infected cells. On the other hand, E6
interacts with p53, leading to degradation via ubiquitin-
dependent proteolysis [60-62].
Since p53 blocks expression of the anti-apoptotic Bcl-2
protein, E6 promotes increased Bcl-2 expression [63].
Thus, it is clear that E6 and E7 complement each other in
promoting an anti-apoptotic effect. Moreover, E6 can act
independently of E7 by stimulating the development of
metastasis in cancer cells by its C-terminal PDZ-ligand
domain, which leads to disruption of normal cell adhesion
[64]. Other proteins such as E4 and E5, as well as E1 and
E2, are involved in viral DNA replication [65].
Despite research on the HPV life cycle and the specific
roles of viral proteins, the mechanism of the HPV life
cycle is not fully understood. Although most HPV 16 is
not directly involved in Bcl-2 activation, it is clear that
there is a connection between E6 and Bcl-2 expression,
which could play a direct role in cancer development.
Extensive investigation has revealed that the HPV 16
oncoprotein E5 plays a crucial role in driving cancerous
mechanisms [66]. E5 is involved in the transformation of
fibroblasts and keratinocytes as well as tumour progression
of skin cancer in transgenic mice via epidermal growth
factor receptor (EGFR) activation [67-69]. Further reports
portray E5 as an additional helper to aid the E6/E7
triggered cancer development process [70]. Following
infection, Bcl-2 family members display differential
expression. Specifically pro-apoptotic Bak and Bax are
decreased, and Bcl-2 levels increase [71]. Such an imbalance
of apoptotic regulators creates a favourable environment for
cancer development and progression. It is still unclear
how each of the Bcl-2 family proteins interacts with
the E5 oncoprotein; however, there is important evidence
for the underlying mechanism of pro-apoptotic Bax
protein regulation by E5 [71]. Bax is inhibited by E5 via
stimulated ubiquitin–proteasome-dependent degradation,
which involves EGFR activation and leads to the sequen-
tial reaction of cyclooxygenase-2 (Cox-2) upregulation.
This results in vascular endothelial growth factor (VEGF)
induction triggering angiogenesis, which is a critical step
of cancer development and metastasis. In addition, Cox-2
induces Prostaglandin E2 (PGE2) which activates the
expression of EP2 and EP4 (PGE2 receptors, G protein
coupled receptor subtypes), cAMP and PKA, leadingto Bax ubiquitination. Hence, E5 inhibits apoptosis by
decreasing the amount of active Bax protein [71].
Human T-cell leukemia virus-1
Human T-cell leukemia virus or HTLV-1 is a member of
the Retroviridae family with a genome consisting of 9 kb
dsRNA [72]. HTLV-1 was the first human retrovirus to
be associated with cancer [73]. It is a causative agent
of adult T-cell leukaemia/lymphoma (ATLL) [74,75].
HTLV-1 is capable of transforming normal peripheral
blood lymphocytes and animal cells in vitro and can
cause tumours in transgenic mice [76,77].
As with most other viruses, HTLV-1 has strategies to
evade apoptosis to fight host cell defense mechanisms.
Cells infected with this virus, as well as ATLL cells,
demonstrate resistance to pro-apoptotic stimuli, such as
gamma irradiation and DNA damage [78]. Unlike other
viruses discussed in this review, HTLV-1 does not have
cellular homologues of anti-apoptotic proteins [78,79].
Instead, HTLV-1 expresses Tax (transactivator protein X),
which has a potent ability to modulate both cellular and
viral genes [75,80-82]. Tax protects HTLV-1-infected cells
from cell cycle arrest and apoptosis, which usually occurs
in cells with mitotic checkpoint dysfunction or irreparable
DNA damage [78]. Tax is one of the most studied proteins
of HTLV-1 [78]. Together with its anti-apoptotic effect,
Tax causes genome instability and mutations, deregulates
cellular energy exchange, and is able to induce regulatory
factors that activate the replication of T-cells, resulting in
its uncontrolled replication [72,83,84].
Inhibition of apoptosis by expression of Bcl-2 proteins is
a hallmark of haematopoietic malignancies and is com-
monly linked with resistance to therapy [85]. Proteins
expressed by HTLV-1 modulate levels of Bcl-2 family
members. Thus, host gene expression is induced by Tax
via signalling pathways such as NF-κB and AKT [78]. All
of these pathways somehow regulate proteins from the
Bcl-2 family.
In addition, Tax activates anti-apoptotic genes and
downregulates pro-apoptotic genes via activation of
NF-κB, which induces expression of Bcl-xL and Bcl-2
[86,87]. By inducing expression of Bcl-xL, Tax increases
survival of cells infected with HTLV-1 and inhibits apop-
totic signals, leading to leukaemogenesis. Bcl-2 and Bcl-xL
are upregulated in cells infected with HTLV-1. Uncultured
leukaemic cells also had increased expression of Bcl-xL
and this was associated with the severity of the illness.
Moreover, overexpression of Bcl-xL in ATLL cells may
lead to chemoresistance [88-90]. By activating NF-κB, Tax
can also mediate inhibition of CD95-mediated apoptosis
through induction of c-FLIP. c-FLIP induction inhibits
caspase-8, which is not able to truncate Bid, its direct
substrate, and thus cannot induce cytochrome c release.
Moreover, Tax increases Bcl-xL expression [91].
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tein Bfl1 while HTLV-1-negative cells do not, indicating
that Bfl1 expression is Tax-dependent, although other viral
proteins may be involved in Bfl1 induction. Tax induces
Bfl1 expression via NF-κB (canonical and alternative) and
AP-1 pathways. Furthermore, inhibition of Bfl1 and Bcl-xL
(but not Bcl-2) leads to sensitisation of HTLV-1 infected T-
cells, making these proteins crucial for T-cell survival [85].
Tax can potently repress pro-apoptotic Bax expression.
This Tax-dependent downregulation of Bax leads to an
altered ratio of Bcl-2 to Bax, which favours cell survival
over apoptosis [92,93], as the ratio of Bcl-2 to Bax is an
important determinant of programmed cell death. p12, a
small protein encoded by HTLV-1, activates IL-2 receptors
and stimulates Jak1/3 which, in turn, activates STAT5.
STAT5 induces expression of anti-apoptotic genes such as
Bcl-xL [78] and downregulation of pro-apoptotic pro-
teins, such as Bcl-2-antagonist/killer 1 (BAK1), and anti-
apoptotic Bcl-2-associated athanogene 4 (BAG4) [94].
Tax modulates an anti-apoptotic effect through regula-
tion of several Bcl-2 family members. It induces Bcl-xL,
Bcl-2, and Bfl1, but suppresses Bax via the NF-kB pathway.
Tax is important for protecting HTLV-1-infected cells
from caspase-dependent apoptosis and progression of
leukaemogenesis.
Hepatitis C Virus (HCV)
Hepatitis C virus (HCV) is a single-stranded RNA virus
of the Hepacivirus genus in the Flaviviridae family. It
is the only positive-stranded RNA virus among the
known human oncogenic viruses. It has an approximately
9.6 kb genome that contains an ORF, which encodes a
3000 amino acid poly protein precursor [1,95]. HCV
employs effective viral immune strategies to achieve a life-
long infection. This persistent infection is strongly linked
to hepatic sclerosis, hepatitis, cirrhosis, and hepatocellular
carcinoma (HCC) [1], where elevated Bcl-2 expression in
liver diseases can lead to the development of HCC [96].
HCV-associated cancers, particularly HCC, pose a major
health concern, as it is the sixth most common cancer
worldwide. Hepatocarcinogenesis results from dysregula-
tion of the balance between cell death and proliferation.
One such mechanism is overexpression of Bcl-xL in HCC
cells, which reduces apoptosis [97].
Bcl-2 inhibits apoptosis and contributes to cell survival
and resistance to cell damage. Bcl-2 family members
regulate cell death and correlate with the progression
and pathogenesis of cancers [96]. The molecular mechan-
ism by which Bcl-2 expression leads to HCC in patients
with chronic HCV infection remains unknown. However, it
is clear that HCV activates Bcl-2 expression, which regu-
lates the STAT3 signalling pathway, leading to regulation of
gene expression during HCV infection [96]. Certainly,
multiple functions of HCV proteins impact cell signalling,indicating that both host cell and viral factors play a role in
HCC [1].
HCV infection leads to the activation of proteins involved
in antiviral response, including interferons (INFs), inter-
feron regulatory factors (IRFs), interferon stimulated genes
(ISGs), signal transducers and activators of transcription
(STATs), and NF-κB [1]. Recent findings have demon-
strated that some HCCs are resistant to Fas-mediated
apoptosis either directly through the expression of HCV
proteins or indirectly through upregulation of Bcl-2 family
members. Bcl-2 inhibits apoptosis either by preventing the
release of cytochrome c or by interfering with the recruit-
ment of pro-caspase 8 to Fas receptors [98]. Furthermore,
HCV inhibits apoptosis at the mitochondrial level through
augmentation of Bcl-xL expression, caused by inhibition of
caspase-3 activation [98].
HCV encodes structural proteins, such as the core
protein and E1 and E2 proteins that form a virus
particle, as well as non-structural proteins that are
expressed in hepatocyte cell lines [99]. Recent studies
report that the HCV core protein may perturb apoptosis
either by inhibition or induction of apoptosis. STAT3 is
activated upon direct interaction with the core protein,
resulting in upregulation of anti-apoptotic Bcl-xL, leading
to excessive cell proliferation [100]. Moreover, Bcl-xL
expression is exerted through the core-dependent kinase
pathway, resulting in caspase-3 inhibition, which leads to
inhibition of apoptotic cell death [101]. Core-dependent
induction of apoptosis involves the Bcl-2 family member
Bax, which is activated indirectly and is important for the
mitochondrial apoptosis signalling pathway [102].
HCV’s non-structural protein 5A (NS5A) plays an
important role in viral replication, survival and pathogen-
esis [103-105]. Recent studies reveal that NS5A employs
various strategies to interfere with apoptotic cell death;
however, the exact molecular mechanisms are yet to be
identified [106]. NS5A interacts with FK506-binding pro-
tein 38 (FKBP38) and shows structural homology in the
BH1, BH2 and BH3 domains of Bcl-2, thus transmitting
the anti-apoptotic function of the Bcl-2 protein to the
mitochondrial outer membrane [107,108]. Moreover,
NS5A interacts with Bax to inhibit its pro-apoptotic
function in hepatocellular carcinoma [109].
Recent studies have shown that over-expression of
SMAD3, a major TGF-β signalling transducer, reduces
susceptibility to HCC by sensitising hepatocytes to apop-
tosis via Bcl-2 downregulation [97,98]. However, elevated
SMAD3 levels are found infrequently and are sometimes
present in other forms of cancers, such as pancreatic
cancer and colorectal cancer [98].
A potential role for antivirals in cancer treatment
It is of great therapeutic importance to understand how
viruses mimic host proteins to inhibit apoptosis. Several
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and its close relatives is a major component of chemore-
sistance. For example, based on the National Cancer
Institute (NCI) panel of 60 diverse cancer cell lines,
Bcl-xL expression levels strongly correlate with resistance
to most chemotherapeutic agents [113].
Regarding EBV, at least five latent viral genes must be
expressed for еру-transformation of B-cells: EBNA-1,
EBNA-2, EBNA-3a, EBNA-3c and LMP-1 [114], where
LMP-1 most closely mimics a classical oncogene. Previous
gene transfer research demonstrates that EBV-encoded
LMP-1 mediates viral transformation and protects
from cell death, in part by induction of the anti-apoptotic
gene Bcl-2 [115]. Therefore, LMP-1 suppression is
critical for maintaining cell growth and survival in
EBV-immortalised cells.
When targeting LMP-1 with antisense oligodeoxynucleo-
tides in EBV lymphoblastoid cells, the oligodeoxynucleo-
tides targets codons one to five of the LMP-1 open-reading
frames and suppresses the levels of LMP-1 in EBV-positive
lymphoblastoid cell lines, inhibiting its function [116].
Furthermore, treatment with Bcl-2 antisense substances
significantly delays development of fatal EBV-positive lym-
phoproliferative disease [117]. Inhibition of proliferation,
decreased expression of Bcl-2, induction of apoptosis, and
high sensitivity to chemotherapeutic agents are associated
with LMP-1 suppression. These observations suggest
that LMP-1 suppression in EBV-associated malignancy
could be a therapeutic target for cancer treatment,
and Bcl-2 antisense therapy may represent a novel
anti-tumour treatment strategy.
HCMV is another potential target for cancer therapeu-
tics. For instance, HCMV induces expression of Bcl-2 in
neuroblastoma cells, resulting in apoptosis inhibition
and chemoresistance. Antiviral medications, such as
Ganciclovir, reverse these processes and are effective
against cancer [118]. Ganciclovir specifically suppresses
viral DNA polymerase activity, while another antiviral
drug, Fomivirsen, is an antisense RNA formulation,
which disrupts the functioning of the viral mRNA [119].
Unfortunately, HCMV develops resistance to antiviral
therapy [120]. Since HCMV secretes a viral homologue
of interleukin (IL)–10, which is detected in glioma stem
cells [121], it is possible to adapt a therapeutic method
based on targeting HCMV-secreted IL–10 to combat
HCMV-related cancers [122].
Therapeutic methods such as radiation therapy, chemo-
therapy, and surgical excision are not efficient enough to
combat KSHV tumours [123]. Perhaps targeting specific
molecules that alter signalling pathways in tumour cells
will be a more efficient therapeutic method. Nutlin-3a,
murine double minute 2 (MDM2) inhibitor, destabilises
the complex formed by the MDM2, p53, and KSHV
latency-associated nuclear antigen (LANA), which triggerslarge-scale apoptosis in KSHV-induced primary effusion
lymphoma (PEL) cells [124]. This method of reactivating
the p53 pathway is a possible treatment option for
KSHV-induced lymphomas. Another potential treatment
strategy for KSHV patients is RNA interference. A short
hairpin RNA delivered by lentiviral vectors acted on the
KHSV genome in the murine PEL model. In particular,
viral cyclin (vcyclin), vFLIP and LANA were targeted. As a
result, PEL cell lines exhibited apoptosis and ascites
development was inhibited [125].
The cells of dermal Kaposi’s sarcoma are associated
with high levels of phosphorylated Akt, p70S6 kinase,
endothelial growth factor (VEGF), and Flk–1/KDR
(fetal liver kinase-1) protein [126]. As the immunosup-
pressive drug Sirolimus (rapamycin) specifically targets
phosphorylated Akt and p70S6 kinase, it is an effective
treatment for Dermal Kaposi’s sarcoma. After three
months of treatment with Sirolimus, there was a total dis-
appearance of dermal Kaposi’s sarcoma symptoms [126].
Over 90% of cervical cancers are HPV positive [127].
One strategy for reducing the prevalence of cervical
cancer is to prevent HPV infections. Recent options
for HPV prevention include vaccination. A quadrivalent
HPV vaccine study has shown that the vaccine effectively
protects women from high-risk vulvar, cervical, and
vaginal lesions of HPV 6, 11, 16 and 18 for up to a
3 years post-vaccination [128]. A 4-year trial of a prevent-
ive human papillomavirus HPV16/18 vaccine adju-
vanted with AS04 (consisting of aluminum hydroxide
and 3-O-desacyl-4′-monophosphoryl lipid A) (Cervarix,
GlaxoSmithKline) indicates up to 100% efficacy against cer-
vical intraepithelial neoplasia grade 2+ (CIN2+) associated
with HPV 16/18, although efficacy lessens as patient age
increases [129].
Therapeutic vaccines of various structure and compos-
ition targeting E6 and E7 are also widely studied. These
include viral/bacterial vector-based, protein and peptide-
based, and RNA/DNA-based vaccines, which all show
significant protection in mice [130]. Furthermore, when
mice are treated with adenovirus vector co-transfected
with HPV 16 E5 genome-based recombinant tumour
vaccine, they display a reduction of cervical tumour pro-
gression via cytotoxic T-cell lymphocyte development
[131]. As there are many mechanisms of E5 involvement,
such as additional modulation of E6/E7 driven tumorigen-
esis and EGFR activation, these pathways could be
targeted for E5 oncoprotein inhibition and interference.
However, this approach has not yet yielded encouraging
results, and further research should continue [130].
An alternative strategy is to treat HPV infection to
block viral-induced cancer development. Although
several approaches are possible, the most promising
one involves siRNA treatment [127]. Furthermore, E6
mRNA degradation via specific siRNA was successful
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HPV-positive cells [127]. Finally, HPV-negative cells
didn’t show similar results when treated with antiviral
siRNAs, which reveals the specific silencing effect on
HPV-infected cervical carcinoma cells [127].
Untargeted conventional chemotherapy is ineffective
for ATLL treatment, especially in the acute form of the
disease. Therefore, other treatment regimes that target
either HTLV-1, Tax, or secondary genetic effects
might be required to treat ATLL [132]. An extensive
review of various targeted treatment regimens suggest a
combination of arsenic, IFN and Zidovudine might be suc-
cessful in ATLL treatment, as HTLV-1 load is decreased by
Zidovudine, and Tax is degraded by arsenic/IFN [133].
Other potential ATLL treatment strategies include
antivirals and other agents that can directly induce
apoptosis by inhibiting Bcl-xL, Bcl2, or inducing Bax.
For instance, Ritonavir, an inhibitor of HIV protease,
has an antiproliferative effect on ATLL cells in vitro.
Ritonavir phosphorylates NF-κB, inhibiting its activity
as shown by downregulation of Bcl-xL and other
anti-apoptotic proteins [134]. Diterpenoid oridonin
from Rabdosia rubescens alsoinhibits NF-κB, thus
inhibiting downstream antiapoptotic Bcl-2 proteins. In
ATLL cells, diterpenoid oridonin downregulates Bcl-xL,
but not Bcl-2 [135]. Capsaicin (main component of red
pepper) also inhibits NF-kB, resulting in a change of
Bcl-2/Bax ratio, inhibiting ATLL cell growth [136].
Certain derivative compounds are capable of inducing
apoptosis in ATLL cells and cause fewer side effects
than the compounds from which they were derived.
For instance, EAPB0203, derived from imidazo [1,2a]
quinoxaline, inhibitscIAP1 and Bcl-xL in malignant T-cells
with and without the virus present, and does not have the
proinflammatory effect of imiquimod. This compound
causes a decrease in mitochondrial membrane potential,
the release of cytochrome c, and caspase activation. The
effect of EAPB0203 is reversed by treatment with caspase
inhibitors [137]. Other drugs, used in combination with
conventional drugs, are able to increase their cytotoxic
effects and apoptosis induction. This effect is demonstrated
when the small molecule ABT737 is used in combination
with doxorubicin, vincristine, or etoposide. This promising
drug for the treatment of ATLL interacts with the BH3
binding groove of Bcl-2, Bcl-xL, and Bcl-w. ABT737
induces apoptosis in the ATLL cells of mice, both
in vitro and in vivo. These results could have important
implications for ATLL treatment [90].
There has been major progress in treatments available
for HCV-infected patients. Until recently, the go-to
treatment was a combination of pegylated interferon and
Ribavirin, which failed to eliminate HCV infection in a
large proportion of patients and also produce multiple
severe side effects [138].TNF-related apoptosis-inducing ligand (TRAIL) induces
apoptosis in various transformed cell lines, but not in
normal tissue. HCC cells express TRAIL; however,
over-activation of NF-κB and Bcl-xL in HCC cells
may restrict TRAIL-mediated apoptosis [92]. This has
led to recent interest in the development of new
therapeutic approaches which would sensitise HCC cells
to TRAIL-induced apoptosis [92]. After HCV infection,
the expression of Bcl-xL and Bak fluctuate, and there is a
significant difference in RNA expression levels of both
Bcl-xL and Bcl-2 genes in HCC when compared to
non-infected individuals. Higher levels (or lower levels) of
expression is significantly associated with poorly dif-
ferentiated tumours [93]. The Bak gene induces apoptosis
in HCC cells, despite the presence of high levels of the
anti-apoptotic Bcl-2 family members [93], indicating a
possible therapeutic route for controlling apoptosis in
HCV-infected patients.
Results are not consistent for the combination of
interferon-α and Ribavirin; however, it is a more effective
therapeutic method than interferon- α alone [139].
Treating with a combination of the HCV protease
inhibitor VX −950 and pegylated interferon-α displays an
antiviral effect; however, results remain inconsistent [140].
The development of sofosbuvir, a direct acting antiviral
agent, shows potent activity against HCV and has further
been shown to improve the rates of sustained virological
response. Sofosbuvir a nucleotide analogue (NS5B
polymerase inhibitor), is a potent drug with excellent
tolerability and pan-genotypic activity with a high barrier
to resistance with powerful antiviral activity against all
HCV genotypes. Used in combination with ribavirin, with
or without pegylated interferon, sofosbuvir can produce
high SVR rates following 12–24 weeks of therapy, where
there is no viral presence in the blood [141].
Suppression of HCV RNA polymerases by various
nucleoside and non–nucleoside polymerase inhibitors can
potentially have an antiviral impact [142]. This suggests
that therapies that alter the life cycle of HCV infection,
particularly those that target NS5B RNA-dependent RNA
polymerase and NS3/4A serine proteases, are potential
therapeutic agents for cancer treatment [143].
Conclusion
The Bcl-2 family has emerged as a dominant regulator
of apoptosis in cancer cells. The mitochondrial-mediated
apoptosis pathway is regulated by anti-apoptotic and
pro-apoptotic (Bad, Bax, and Bak) proteins. Defects in
apoptosis signaling directly contribute to tumorigenesis;
therefore, the Bcl proteins are very important players in
apoptosis. By affecting Bcl proteins or their expression
levels, viruses benefit in many ways, such as inhibiting
normal programmed cell death in host cells, which
propagates infection. In this review, we have outlined
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the Bcl-2 family. We have focused on how Herpesviruses,
HTLV-1, HPV and HCV take advantage of various path-
ways to block apoptosis, predisposing cells for malignant
cancer phenotype. To counteract this, we have proposed
possible therapeutics against viral infection, which have
the potential to eliminate Bcl-induced carcinogenesis.
Finally, we speculate to what extent treating viral infections
may advance cancer treatment.
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